BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Su X, Kong Y, Peng D. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease. Clin Chim Acta 2019;498:30-7. [PMID: 31419414 DOI: 10.1016/j.cca.2019.08.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang X, Bai R, Jia Y, Zong J, Wang Y, Dong Y. The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus. Int J Diabetes Dev Ctries 2020;40:491-9. [DOI: 10.1007/s13410-020-00857-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hüttl M, Markova I, Miklankova D, Zapletalova I, Poruba M, Haluzik M, Vaněčkova I, Malinska H. In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia. Int J Mol Sci 2021;22:11513. [PMID: 34768942 DOI: 10.3390/ijms222111513] [Reference Citation Analysis]
3 Chou Y, Ma J, Su X, Zhong Y. Emerging insights into the relationship between hyperlipidemia and the risk of diabetic retinopathy. Lipids Health Dis 2020;19:241. [PMID: 33213461 DOI: 10.1186/s12944-020-01415-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Akbari R, Yaghooti H, Jalali MT, Khorsandi LS, Mohammadtaghvaei N. Capparis spinosa improves the high fat diet-induced non-alcoholic steatohepatitis in rats: the possible role of FGF21. BMC Res Notes 2020;13:356. [PMID: 32723353 DOI: 10.1186/s13104-020-05200-4] [Reference Citation Analysis]
5 Khalafi M, Alamdari KA, Symonds ME, Nobari H, Carlos-Vivas J. Impact of acute exercise on immediate and following early post-exercise FGF-21 concentration in adults: systematic review and meta-analysis. Hormones (Athens) 2021;20:23-33. [PMID: 33151509 DOI: 10.1007/s42000-020-00245-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
6 Xiaolong L, Dongmin G, Liu M, Zuo W, Huijun H, Qiufen T, XueMei H, Wensheng L, Yuping P, Jun L, Zhaolin Z. FGF21 induces autophagy-mediated cholesterol efflux to inhibit atherogenesis via RACK1 up-regulation. J Cell Mol Med 2020;24:4992-5006. [PMID: 32227589 DOI: 10.1111/jcmm.15118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
7 Bryl A, Mrugacz M, Falkowski M, Zorena K. The Effect of Hyperlipidemia on the Course of Diabetic Retinopathy—Literature Review. JCM 2022;11:2761. [DOI: 10.3390/jcm11102761] [Reference Citation Analysis]
8 Li Y, Chen L, Li L, Sottas C, Petrillo SK, Lazaris A, Metrakos P, Wu H, Ishida Y, Saito T, Golden-Mason L, Rosen HR, Wolff JJ, Silvescu CI, Garza S, Cheung G, Huang T, Fan J, Culty M, Stiles B, Asahina K, Papadopoulos V. Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty liver disease. iScience 2021;24:102457. [PMID: 34013171 DOI: 10.1016/j.isci.2021.102457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Su X, Peng H, Chen X, Wu X, Wang B. Hyperlipidemia and hypothyroidism. Clinica Chimica Acta 2022. [DOI: 10.1016/j.cca.2022.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 ZhuGe DL, Javaid HMA, Sahar NE, Zhao YZ, Huh JY. Fibroblast growth factor 2 exacerbates inflammation in adipocytes through NLRP3 inflammasome activation. Arch Pharm Res 2020;43:1311-24. [PMID: 33245516 DOI: 10.1007/s12272-020-01295-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
11 Ruiz-Padilla AJ, Ruiz-Noa Y, Del Rocio Ibarra-Reynoso L, Lazo-de-la-Vega-Monroy ML, Alonso-Castro AJ, Sánchez-Barajas M, Alvarez-Alvarez RM, Del Carmen Preciado-Puga M. FGF21 and its Relationship with Inflammatory and Metabolic Parameters in HIV Patients after Antiretroviral Treatment. Curr HIV Res 2020;18:308-14. [PMID: 32684151 DOI: 10.2174/1570162X18666200719235625] [Reference Citation Analysis]
12 Chen L, Zhang X, Zhang L, Zheng D. Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease. Diabetes Metab Syndr Obes 2020;13:3507-18. [PMID: 33116702 DOI: 10.2147/DMSO.S262284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Yu LY, Li WY, Lin J. Juglanin improves lipid metabolism disorder, liver injury, and intestinal integrity in nonalcoholic fatty liver mice. Shijie Huaren Xiaohua Zazhi 2020; 28(4): 113-121 [DOI: 10.11569/wcjd.v28.i4.113] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Androutsakos T, Nasiri-Ansari N, Bakasis AD, Kyrou I, Efstathopoulos E, Randeva HS, Kassi E. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. Int J Mol Sci 2022;23:3107. [PMID: 35328527 DOI: 10.3390/ijms23063107] [Reference Citation Analysis]
15 Chang GR, Hou PH, Yang WC, Wang CM, Fan PS, Liao HJ, Chen TP. Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice. Pharmaceuticals (Basel) 2021;14:267. [PMID: 33809508 DOI: 10.3390/ph14030267] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
16 Xu N, Luo H, Li M, Wu J, Wu X, Chen L, Gan Y, Guan F, Li M, Su Z, Chen J, Liu Y. β-patchoulene improves lipid metabolism to alleviate non-alcoholic fatty liver disease via activating AMPK signaling pathway. Biomed Pharmacother 2021;134:111104. [PMID: 33341045 DOI: 10.1016/j.biopha.2020.111104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]